Log in to search using one of your social media accounts:

 

Kudos launches solution to illegal sharing of copyright content
http://blog.growkudos.com/2017/11/15/kudos-solution-illegal-sharing-copyright-content Kudos, the award-winning service for maximizing the reach and impact of research publications, has announced the launch of its shareable PDF solution, which helps publishers prevent copyright infringement and reclaim lost usage from sharing of research articles on scholarly collaboration networks (SCNs). Authors of articles published by the American Thoracic Society, Emerald Publishing, FASEB and The IET can now use Kudos to create summary PDFs of their articles, for uploading to sites like ResearchGate and Academia.edu. The summary PDFs...
Source: News from STM - November 15, 2017 Category: Databases & Libraries Authors: STM Publishing News Tags: Editorial Featured Source Type: news

UAB research shows promise for treating cystic fibrosis
UAB research on a new two-drug combination for treating cystic fibrosis is gaining traction. The new drug therapy has been shown to improve lung function in patients with certain mutations of the CFTR gene, which is responsible for the disease.  UAB's findings, published in the New England Journal of Medicine, show the combinations of the drugs Tezacaftor and Ivacaftor improved lung fun ction by nearly 7 percent compared to a placebo in a subset of patients. The UAB study looked at over 200 cystic… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - November 8, 2017 Category: Biotechnology Authors: Tyler Patchen Source Type: news

Battle to get £100,000-a-year cystic fibrosis wonder drug
Campaigners hit out last week at health chiefs who have denied NHS England patients access to the £100,000-a-year medication because it is ‘not cost-effective’. (Source: the Mail online | Health)
Source: the Mail online | Health - November 4, 2017 Category: Consumer Health News Source Type: news

NICE's first guideline on cystic fibrosis endorses telemedicine
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - November 1, 2017 Category: Drugs & Pharmacology Source Type: news

People with cystic fibrosis could be monitored through phone or video messaging says NICE
Patients with cystic fibrosis could avoid having to travel to specialist clinics if health professionals could monitor them using phone or video messaging. (Source: NHS Networks)
Source: NHS Networks - October 26, 2017 Category: UK Health Source Type: news

DNA and RNA editing could cure up to 15,000 diseases
Scientists at MIT and Harvard have discovered a way to use CRISPR technology to cure cystic fibrosis. With this new gene editor, they can now fix any wrong letter in the genome. (Source: the Mail online | Health)
Source: the Mail online | Health - October 25, 2017 Category: Consumer Health News Source Type: news

Gene editing technology can now fix cystic fibrosis
Scientists at MIT and Harvard have discovered a way to use CRISPR technology to cure cystic fibrosis. With this new gene editor, they can now fix any wrong letter in the genome. (Source: the Mail online | Health)
Source: the Mail online | Health - October 25, 2017 Category: Consumer Health News Source Type: news

Some people with cystic fibrosis might live longer because of genetic mutations
(Boston Children's Hospital) Research suggests that genetic mutations to an 'epithelial sodium pathway' could protect against cystic fibrosis and its debilitating effects on the lungs. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 25, 2017 Category: International Medicine & Public Health Source Type: news

Literature review: the economic costs of lung disease and the cost effectiveness of policy and service interventions
Published evidence on the economic costs of lung disease (incl asthma, COPD, cystic fibrosis) and the cost-effectiveness of different NHS activities, programmes and campaigns to combat lung problems. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - October 24, 2017 Category: Consumer Health News Source Type: news

North American Cystic Fibrosis Conference 2017
Date: Tuesday, October 24, 2017Year: 2017Location: Indianapolis, USAContent-type: current_conferences (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 24, 2017 Category: Respiratory Medicine Authors: ROrritt Source Type: news

41st European Cystic Fibrosis Conference
Date: Tuesday, October 24, 2017Year: 2018Location: Belgrade, SerbiaContent-type: current_conferences (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - October 24, 2017 Category: Respiratory Medicine Authors: ROrritt Source Type: news

Laboratory Diagnosis of Non-Tuberculous Mycobacterium Infections in Bronchiectasis Patients: Issues and Controversies
Non-tuberculous mycobacteria (NTM) are environmental microbes that can cause pulmonary infection and are especially problematic in bronchiectasis patients with or without cystic fibrosis (CF). Microbiological identification of NTM in these patients is difficult given the high microbial burden in the lungs and the need to differentiate between colonization and transient and true infection. Determining if and when to initiate antimicrobial treatment against this multi-drug-resistant group of organisms is also challenging. (Source: Clinical Microbiology Newsletter)
Source: Clinical Microbiology Newsletter - October 24, 2017 Category: Microbiology Authors: Kara J. Levinson, Peter H. Gilligan Source Type: news

The Bedside Nurse's Role at End of Life The Bedside Nurse's Role at End of Life
A woman with young children is dying from cystic fibrosis. How does the nurse best offer comfort and closure?Medscape Nurses (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 20, 2017 Category: Consumer Health News Tags: Nursing Viewpoint Source Type: news

The microbial anatomy of an organ
(University of California - San Diego) University of California San Diego researchers have developed the first 3-D spatial visualization tool for mapping 'omics' data onto whole organs. The tool helps researchers and clinicians understand the effects of chemicals, such as microbial metabolites and medications, on a diseased organ in the context of microbes that also inhabit the region. The work could advance targeted drug delivery for cystic fibrosis and other conditions where medications are unable to penetrate. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 19, 2017 Category: International Medicine & Public Health Source Type: news

Visualising Early Lung Disease in CF: The Emergence of MRI Visualising Early Lung Disease in CF: The Emergence of MRI
This editorial discusses the potential role of magnetic resonance imaging in the detection of early lung disease in patients with cystic fibrosis.Thorax (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 10, 2017 Category: Consumer Health News Tags: Pulmonary Medicine Journal Article Source Type: news

Mayo Clinic Q and A: Diagnosing cystic fibrosis
DEAR MAYO CLINIC: Recently, my niece was diagnosed with cystic fibrosis at 16. No one else in our family has been diagnosed with it, and, until recently, she didn?t have any symptoms. Now I?m worried about my kids, ages 4 and 6. Their newborn screenings for cystic fibrosis were negative, but should I have them [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - September 29, 2017 Category: Databases & Libraries Source Type: news

Flu warning: Your persistent cough could be THIS deadly genetic condition
FLU symptoms include a cough and stuffy nose, but they are also signs of a deadly genetic condition called cystic fibrosis. (Source: Daily Express - Health)
Source: Daily Express - Health - September 21, 2017 Category: Consumer Health News Source Type: news

Read Jimmy Kimmel ’s Moving Healthcare Monologue That Everyone’s Talking About
On Tuesday night, Jimmy Kimmel took to his late night show once more to talk healthcare — a subject near and dear to him personally, after his infant son dealt with heart surgery in the days after his birth last May. He delivered a heartfelt monologue then about the importance of adequate health coverage for all Americans, and in the wake of new healthcare legislation from Senators Bill Cassidy and Lindsay Graham, he returned to the subject with an emotional plea. I know you guys are going to find this hard to believe, but a few months ago, after my son had open heart surgery, which was something I spoke about on the...
Source: TIME.com: Top Science and Health Stories - September 20, 2017 Category: Consumer Health News Authors: Raisa Bruner Tags: Uncategorized Healthcare Jimmy Kimmel Late Night Television Source Type: news

Air Pollution Linked to MRSA Acquisition in Children With CF Air Pollution Linked to MRSA Acquisition in Children With CF
Young cystic fibrosis patients chronically exposed to air pollution may be more likely to acquire MRSA, a new study reports.BMC Pulmonary Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 20, 2017 Category: Consumer Health News Tags: Pulmonary Medicine Journal Article Source Type: news

Bacteremia and Fungemia in CF Patients With FPE Bacteremia and Fungemia in CF Patients With FPE
Are these pathogens present in cystic fibrosis patients experiencing febrile pulmonary exacerbation?BMC Pulmonary Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 15, 2017 Category: Consumer Health News Tags: Pulmonary Medicine Journal Article Source Type: news

The Emergence of Streptococcus anginosus Group as a Cystic Fibrosis Pathogen
Molecular profiling studies have identified potential emerging pathogens, such as Streptococcus anginosus group, that may play a role in cystic fibrosis (CF) lung disease by either directly causing infection or upregulating the virulence factors of classic CF pathogens, such as Pseudomonas aeruginosa. Routine surveillance of CF pathogens using traditional microbiology culture guides treatment and management of CF patients; however, routine CF culture protocols have not been modified to select for, detect, and further determine the role these emerging pathogens play in the progression of CF lung disease. (Source: Clinical M...
Source: Clinical Microbiology Newsletter - September 7, 2017 Category: Microbiology Authors: Emily M. Hill Source Type: news

Atlant Clinical to Complete Phase II Study in Patients with Cystic Fibrosis
Atlant Clinical has successfully completed an international, multicenter, randomised, placebo-controlled study in patients with cystic fibrosis. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - September 7, 2017 Category: Pharmaceuticals Source Type: news

ProQR concludes QR-010 dosing in Phase Ib trial to treat cystic fibrosis
The Netherlands-based ProQR Therapeutics has concluded dosing patients in a Phase Ib clinical trial of QR-010 for the treatment of patients with cystic fibrosis. (Source: Drug Development Technology)
Source: Drug Development Technology - August 30, 2017 Category: Pharmaceuticals Source Type: news

Scientists can now grow 'mini organs' for each patient
A Dutch lab is growing mini organs for cystic fibrosis patients to see how drugs would affect them without the risks of trying it. Els van de Heijden (pictured) is one of their patients. (Source: the Mail online | Health)
Source: the Mail online | Health - August 23, 2017 Category: Consumer Health News Source Type: news

Lab-made "mini organs" helping doctors treat cystic fibrosis
Doctors in the Netherlands are taking a novel approach to treat cystic fibrosis: They're growing miniature organs for every patient in the country. (Source: ABC News: Health)
Source: ABC News: Health - August 23, 2017 Category: Consumer Health News Tags: Health Source Type: news

Sweet! Sugar-coated probe yields better acid test
(Michigan Technological University) When our cells' acid-alkaline balance goes wrong, it can go wrong in a big way--think cancer and cystic fibrosis. New fluorescent probes make it easier to detect pH and sweetened the deal by adding sugar to his acid-sensitive probes, making them much friendlier to living tissue. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 11, 2017 Category: Cancer & Oncology Source Type: news

'Keep them well': New cystic fibrosis medications move closer to a cure
Results of a new drug trial suggest the next generation of medications, known as CFTR modulators, show potential to correct the genetic defect that causes cystic fibrosis and halt the disease's destructive progression. (Source: CBC | Health)
Source: CBC | Health - August 7, 2017 Category: Consumer Health News Tags: News/Health Source Type: news

Rugby Laboratories Issues Voluntary Nationwide Recall of Diocto Liquid and Diocto Syrup Manufactured By PharmaTech, LLC Due to Possible Product Contamination
Rugby ® Laboratories of Livonia, MI is voluntarily recalling all lots within the expiry of Diocto Liquid and Diocto Syrup, (docusate sodium solutions) manufactured by PharmaTech, LLC of Davie, FL due to a risk of product contamination with Burkholderia cepacia. If a product contains B. cepacia, its use c ould result in infections in patients with compromised immune systems and in patients with chronic lung conditions such as cystic fibrosis. Some of these infections may be serious or even life-threatening in the at-risk patient population. (Source: Food and Drug Administration)
Source: Food and Drug Administration - August 3, 2017 Category: Food Science Source Type: news

End of genetic diseases? Congenital heart disease removed from embryos for the first time
INHERITED illnesses from cancer to cystic fibrosis could be wiped out after congenital heart disease was removed from embryos for the first time. (Source: Daily Express - Health)
Source: Daily Express - Health - August 2, 2017 Category: Consumer Health News Source Type: news

Eloxx Pharmaceuticals Secures US$8 Million Investment from LSP, Increasing Total Raised in Series C to US$38 Million
Financing to support advancement of novel disease-modifying therapy targeting genetic diseases, including cystic fibrosis SAN DIEGO and REHOVOT, Israel, Aug. 2, 2017 -- (Healthcare Sales & Marketing Network) -- Sevion Therapeutics, Inc. (OTCQB: SVON) a... Biopharmaceuticals, Venture Capital Eloxx Pharmaceuticals, Cystic Fibrosis, Duchene Muscular Dystrophy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 2, 2017 Category: Pharmaceuticals Source Type: news

Respiratory Microbiome May Influence Inflammation in CF
Less diversity linked to lower IL - 8 concentration, neutrophil count in infants with cystic fibrosis (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - July 31, 2017 Category: Respiratory Medicine Tags: Infections, Pediatrics, Pharmacy, Pulmonology, Journal, Source Type: news

Sweat test developed to identify cystic fibrosis in infants
Researchers have developed a method to test the chemical composition of sweat to test for cystic fibrosis in screen-positive infants. (Source: Health News - UPI.com)
Source: Health News - UPI.com - July 31, 2017 Category: Consumer Health News Source Type: news

Scientists discover biomarkers which could lead to better treatments for CF pat
(McMaster University) Researchers have identified two new biological markers of cystic fibrosis (CF), a genetic disease which affects children and young adults, leaving them with lifelong health complications including digestive problems and persistent lung infections.The findings, published in the journal ACS Central Science, shed new light on the underlying mechanisms of CF and could lead to improved prognosis and better therapies for a disease which is quite variable, affecting different children in different ways, say researchers. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 31, 2017 Category: International Medicine & Public Health Source Type: news

Toward a better sweat test for babies with cystic fibrosis
(American Chemical Society) Cystic fibrosis (CF) is an incurable genetic disease in which patients have chronic lung infections. The sooner CF is diagnosed, the better the symptoms can be managed. But current tests can give ambiguous results that do not reflect disease progression. Today, in ACS Central Science, researchers reveal a new type of sweat test that can overcome this challenge. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 31, 2017 Category: International Medicine & Public Health Source Type: news

Scientists discover biomarkers which could lead to better treatments for CF patients
(McMaster University) Researchers have identified two new biological markers of cystic fibrosis (CF), a genetic disease which affects children and young adults, leaving them with lifelong health complications including digestive problems and persistent lung infections.The findings, published in the journal ACS Central Science, shed new light on the underlying mechanisms of CF and could lead to improved prognosis and better therapies for a disease which is quite variable, affecting different children in different ways, say researchers. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - July 31, 2017 Category: Biology Source Type: news

Aradigm Submits New Drug Application (NDA) to FDA for U.S. Marketing Approval of Linhaliq in Non-Cystic Fibrosis Bronchiectasis
HAYWARD, Calif.--(BUSINESS WIRE) July 27, 2017 -- Aradigm Corporation (NASDAQ: ARDM) (the " Company " ) today announced it has submitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Linhaliq ™ for the treatment of... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - July 27, 2017 Category: Drugs & Pharmacology Source Type: news

As more adults are diagnosed with cystic fibrosis, radiologists look for patterns
(American Roentgen Ray Society) Marked improvements have been made over the past few decades in managing cystic fibrosis, but as more adults are diagnosed with the disease radiologists can do more to monitor the wide spectrum of CF in adults, including nonclassic imaging findings, according to an article published in the July 2017 issue of the American Journal of Roentgenology (AJR). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 26, 2017 Category: International Medicine & Public Health Source Type: news

Antabio to develop treatment for Pseudomonas infections in cystic fibrosis patients
French biopharmaceutical company Antabio has secured a non-dilutive funding to accelerate the development of a new small molecule drug to treat chronic Pseudomonas infections in cystic fibrosis patients. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - July 25, 2017 Category: Pharmaceuticals Source Type: news

New hope in battle to find cystic fibrosis cure
Professor Jane Davies, honorary consultant in paediatric medicine at London ’s Royal Brompton Hospital, said if the ‘very, very early’ results held up, triple-therapies could be used to across the world. (Source: the Mail online | Health)
Source: the Mail online | Health - July 23, 2017 Category: Consumer Health News Source Type: news

Vertex Reports Positive Results for Cystic Fibrosis Triple Combos Vertex Reports Positive Results for Cystic Fibrosis Triple Combos
Vertex Pharmaceuticals Inc on Tuesday said three different triple combinations of cystic fibrosis treatments significantly improved patient lung function in clinical trials, bolstering its goal of a therapy that could help up to 90 percent of patients with the life-shortening lung disease.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 19, 2017 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Vertex Pharma shares hit life high as cystic fibrosis data wows
(Reuters) - Shares of Vertex Pharmaceuticals Inc soared to touch a record high on Wednesday, a day after the drugmaker revealed data on its triple combinations of cystic fibrosis (CF) treatments that wowed both analysts and investors. (Source: Reuters: Health)
Source: Reuters: Health - July 19, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Pharma Technology Focus – Issue 61
In this issue: The UK ’s healthcare spending problem, PhRMA’s new R&D spending requirements, undermining supply chain security by importing foreign drugs, milestone cystic fibrosis trials, a personalised treatment approach for panic disorder, and more … (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - July 19, 2017 Category: Pharmaceuticals Source Type: news

Cystic fibrosis: searching for a breakthrough
There are exciting years ahead for the treatment of cystic fibrosis (CF). This inherited autosomal recessive genetic disorder has proven to be incredibly tough for drug developers, with research efforts hampered by the formidable scientific challenge … (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - July 18, 2017 Category: Pharmaceuticals Source Type: news

Vertex spikes on good news for cystic fibrosis drugs
(Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - July 18, 2017 Category: Pharmaceuticals Source Type: news

Vertex reports positive results for cystic fibrosis triple combos
(Reuters) - Vertex Pharmaceuticals Inc said on Tuesday three different triple combinations of cystic fibrosis treatments significantly improved patient lung function in clinical trials, bolstering its goal of a therapy that could help up to 90 percent of patients with the life-shortening lung disease. (Source: Reuters: Health)
Source: Reuters: Health - July 18, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Vertex cystic fibrosis drug cocktails appear to hit the mark in trials
Shares of Vertex Pharmaceuticals soared in after-hours trading Tuesday after the company announced that three separate combinations of its experimental cystic fibrosis drugs had performed well in early- and mid-stage trials. The news brings the Boston-based company one important step closer to developing a treatment for nearly all patients with the lung disease. It also boosted its stock by around 25 percent by 4:30 p.m. If the stock increase holds until tomorrow's open, it would add nearly $9 billion… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - July 18, 2017 Category: American Health Authors: Max Stendahl Source Type: news

Vertex cystic fibrosis drug cocktails appear to hit the mark in trials
Shares of Vertex Pharmaceuticals soared in after-hours trading Tuesday after the company announced that three separate combinations of its experimental cystic fibrosis drugs had performed well in early- and mid-stage trials. The news brings the Boston-based company one important step closer to developing a treatment for nearly all patients with the lung disease. It also boosted its stock by around 25 percent by 4:30 p.m. If the stock increase holds until tomorrow's open, it would add nearly $9 billion… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - July 18, 2017 Category: Biotechnology Authors: Max Stendahl Source Type: news

' Just What We Dreamed.' New Vertex Drugs Show Dramatic Benefit Against Cystic Fibrosis
Three different three-drug regimens all provided dramatic results against cystic fibrosis, a fatal disease of the lungs and digestive system that afflicts 75,000 people. “This is just what we dreamed would someday happen,” says Francis Collins, the director of the National Institutes of Health (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - July 18, 2017 Category: Pharmaceuticals Authors: Matthew Herper, Forbes Staff Tags: NASDAQ:VRTX NASDAQ:GLPG Source Type: news

Two recent scientific advances underscore an encouraging future for precision medicine at FDA
By: Janet Woodcock, M.D. FDA helps bring precision medicine – in the form of targeted therapies — to people living with diseases that have specific genetic features. Two recent FDA drug approvals point to an encouraging future for “precision medicine” — an approach for disease treatment that tailors medical therapies, including medications, to the needs of individual patients. These approvals involve diseases resulting from particular genetic characteristics identified by laboratory testing. In mid-May, FDA announced that we expanded the approval of Kalydeco (ivacaftor), enabling a larger num...
Source: Mass Device - July 17, 2017 Category: Medical Devices Authors: Danielle Kirsh Tags: Blog FDA Voice Source Type: news

Vertex inks another reimbursement deal in Europe for top-selling drug
Since winning FDA approval in 2015 for Orkambi, Vertex Pharmaceuticals has been slowly expanding access to the pricey cystic fibrosis drug across Europe by signing reimbursement deals with various countries. On Thursday, Boston-based Vertex (Nasdaq: VRTX) said it had inked another reimbursement deal for Orkambi, its best-selling drug, this time with officials in Italy. The agreement with the Italian Medicines Agency will make the drug available to “hundreds of eligible patients” in the country… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - July 13, 2017 Category: American Health Authors: Max Stendahl Source Type: news